昊帆生物 (301393.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	639.0M	602.3M	451.9M	388.8M	447.5M
Cost of Revenue	420.7M	392.5M	269.9M	238.9M	253.9M
Gross Profit	218.3M	209.8M	182.0M	149.9M	193.6M
Operating Expenses
R&D Expense	41.8M	40.9M	36.0M	28.5M	22.3M
SG&A Expense	—	—	—	—	—
General & Admin Expense	42.2M	36.9M	29.5M	24.0M	15.7M
Selling & Marketing Expense	16.5M	16.4M	13.6M	12.0M	9.5M
Other Expenses	—	—	—	—	—
Total Operating Expenses	103.1M	92.5M	50.5M	39.7M	46.9M
Cost and Expenses	523.8M	485.0M	320.3M	278.6M	300.8M
Operating Income (EBIT)	141.6M	144.3M	155.9M	112.6M	149.2M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	126.5M	129.3M	154.6M	112.5M	149.0M
Income Tax Expense	17.8M	18.4M	20.6M	13.5M	19.6M
Bottom Line
Net Income	113.3M	114.7M	134.1M	99.0M	129.4M
Earnings from Cont. Ops	108.8M	110.8M	134.1M	99.0M	129.4M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	113.3M	114.7M	134.1M	99.0M	129.4M
Per Share
Basic EPS	CN¥1.06	CN¥1.07	CN¥1.25	CN¥1.07	CN¥1.60
Diluted EPS	CN¥1.06	CN¥1.07	CN¥1.24	CN¥1.07	CN¥1.60
Revenue Per Share	CN¥5.92	CN¥5.62	CN¥4.20	CN¥4.20	CN¥5.53
Shares
Basic Shares Outstanding	107.9M	107.2M	107.5M	92.5M	80.9M
Diluted Shares Outstanding	107.9M	107.2M	107.5M	92.5M	80.9M
Profitability Metrics
EBITDA	—	180.7M	174.2M	125.7M	159.8M
D&A	—	36.5M	18.3M	13.1M	10.5M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026